caa a22 4500 467906912 CHVBK 20180406152837.0 cr unu---uuuuu 170328e20060701xx s 000 0 eng 10.1007/s00251-006-0111-8 doi (NATIONALLICENCE)springer-10.1007/s00251-006-0111-8 LOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas [Elektronische Daten] [Isabel Maleno, Jose Romero, Teresa Cabrera, Laura Paco, Natalia Aptsiauri, Jose Cozar, Miguel Tallada, Miguel López-Nevot, Federico Garrido] Alterations in HLA class I antigen expression have been frequently described in different epithelial tumors and are thought to favor tumor immune escape from T lymphocyte recognition. Multiple molecular mechanisms are responsible for these altered HLA class I tumor phenotypes. Some are structural defects that produce unresponsiveness to treatment with interferons. Others include alterations in regulatory mechanisms that can be switched on by treatment of tumor cells with different cytokines. One important mechanism belonging to the first group is loss of heterozygosity (LOH) at chromosome region 6p21.3, which can lead to HLA haplotype loss. In this investigation, the frequency of LOH at 6p21 chromosome region was studied in 69 bladder carcinomas. Short tandem repeat analysis showed that 35% of cases had LOH in this chromosome region. By considering these results together with immunohistological findings previously published by our group, we identified a distribution pattern of HLA class I altered phenotypes in bladder cancer. The most frequently altered phenotype in bladder carcinomas was total loss of HLA class I expression (17 cases, 25%), followed by phenotype II associated with HLA haplotype loss (12 cases, 17.5%), and HLA allelic loss (ten cases, 14.5%). Nine cases (13%) were classified as having a compound phenotype, five cases (7%) as having HLA locus loss, and in 16 cases (23%) no alteration in HLA expression was detected. An important conclusion of this report is that a combination of different molecular and immunohistological techniques is required to precisely define which HLA alleles are lost during tumor progression and to characterize the underlying mechanisms of these losses. These studies should be performed when a cancer patient is to be included in an immunotherapy protocol that aims to stimulate different immune effector mechanisms. Springer-Verlag, 2006 Bladder carcinoma nationallicence HLA class I nationallicence Tumor escape nationallicence Tumor prognostic factor nationallicence Maleno Isabel Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut Romero Jose Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut Cabrera Teresa Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut Paco Laura Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut Aptsiauri Natalia Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut Cozar Jose Servicio de Urología, Hospital Universitario Virgen de las Nieves, 18014, Granada, Spain aut Tallada Miguel Servicio de Urología, Hospital Universitario Virgen de las Nieves, 18014, Granada, Spain aut López-Nevot Miguel Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut Garrido Federico Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut Immunogenetics Springer-Verlag 58/7(2006-07-01), 503-510 0093-7711 58:7<503 2006 58 251 https://doi.org/10.1007/s00251-006-0111-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00251-006-0111-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Maleno Isabel Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut NATIONALLICENCE 700 1- Romero Jose Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut NATIONALLICENCE 700 1- Cabrera Teresa Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut NATIONALLICENCE 700 1- Paco Laura Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut NATIONALLICENCE 700 1- Aptsiauri Natalia Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut NATIONALLICENCE 700 1- Cozar Jose Servicio de Urología, Hospital Universitario Virgen de las Nieves, 18014, Granada, Spain aut NATIONALLICENCE 700 1- Tallada Miguel Servicio de Urología, Hospital Universitario Virgen de las Nieves, 18014, Granada, Spain aut NATIONALLICENCE 700 1- López-Nevot Miguel Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut NATIONALLICENCE 700 1- Garrido Federico Dept. de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Avd. Fuerzas Armadas 2, 18014, Granada, Spain aut NATIONALLICENCE 773 0- Immunogenetics Springer-Verlag 58/7(2006-07-01), 503-510 0093-7711 58:7<503 2006 58 251 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer